Cargando…
The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity
CAR T-cell therapy is well tolerated and effective in patients with Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). However, even second- generation anti-CD30 CAR T-cells with CD28 (28z) costimulatory domains failed to achieve the desired rate of complete responses. In the present s...
Autores principales: | Zhang, Shangkun, Gu, Chaojiang, Huang, Lifang, Wu, Han, Shi, Jiangzhou, Zhang, Zijian, Zhou, Yong, Zhou, Jingjiao, Gao, Yang, Liu, Jiaxing, Leng, Yingqi, Liu, Xiyu, Zhang, Qinxing, Huang, Liang, Tong, Xiqin, Young, Ken H., Li, Jiapeng, Zhu, Haichuan, Zhang, Tongcun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213494/ https://www.ncbi.nlm.nih.gov/pubmed/35729339 http://dx.doi.org/10.1038/s41598-022-14523-0 |
Ejemplares similares
-
CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity
por: Shi, Jiangzhou, et al.
Publicado: (2021) -
CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities
por: Ren, Anqi, et al.
Publicado: (2023) -
Dynamic Expression of EpCAM in Primary and Metastatic Lung Cancer Is Controlled by Both Genetic and Epigenetic Mechanisms
por: Cui, Yeting, et al.
Publicado: (2022) -
Long‐term outcomes of relapsed/refractory double‐hit lymphoma (r/r DHL) treated with CD19/22 CAR T‐cell cocktail therapy
por: Wei, Jia, et al.
Publicado: (2020) -
Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30(+) lymphoma
por: Zhang, Peiling, et al.
Publicado: (2022)